141 related articles for article (PubMed ID: 33771286)
1. Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders.
Miguel AQC; Smith CL; Burduli E; Roll JM; McPherson S
J Subst Abuse Treat; 2021 May; 124():108291. PubMed ID: 33771286
[TBL] [Abstract][Full Text] [Related]
2. Effect of Low-Frequency Repetitive Transcranial Magnetic Stimulation on Impulse Inhibition in Abstinent Patients With Methamphetamine Addiction: A Randomized Clinical Trial.
Yuan J; Liu W; Liang Q; Cao X; Lucas MV; Yuan TF
JAMA Netw Open; 2020 Mar; 3(3):e200910. PubMed ID: 32167568
[TBL] [Abstract][Full Text] [Related]
3. Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence.
Brensilver M; Heinzerling KG; Swanson AN; Shoptaw SJ
Exp Clin Psychopharmacol; 2012 Oct; 20(5):430-5. PubMed ID: 22867036
[TBL] [Abstract][Full Text] [Related]
4. Validating the clinical relevance of alternative stimulant use treatment outcome measures by examining their association with 3-month follow-up outcomes.
Miguel AQC; Smith CL; Burduli E; Roll JM; McPherson SM
Exp Clin Psychopharmacol; 2021 Jun; 29(3):288-293. PubMed ID: 34264739
[TBL] [Abstract][Full Text] [Related]
5. Process-of-care measures as predictors of client outcome among a methamphetamine-dependent sample at 12- and 36-month follow-ups.
Rawson RA; Gonzales R; Greenwell L; Chalk M
J Psychoactive Drugs; 2012; 44(4):342-9. PubMed ID: 23210383
[TBL] [Abstract][Full Text] [Related]
6. What defines a clinically meaningful outcome in the treatment of substance use disorders: reductions in direct consequences of drug use or improvement in overall functioning?
Kiluk BD; Fitzmaurice GM; Strain EC; Weiss RD
Addiction; 2019 Jan; 114(1):9-15. PubMed ID: 29900624
[TBL] [Abstract][Full Text] [Related]
7. Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence.
Brandt L; Hu MC; Nunes EV; Campbell ANC
Drug Alcohol Depend; 2023 Jul; 248():109918. PubMed ID: 37224673
[TBL] [Abstract][Full Text] [Related]
8. Short and long-term improvements in psychiatric symptomatology to validate clinically meaningful treatment outcomes for cocaine use disorders.
Miguel AQC; Kiluk BD; Babuscio TA; Nich C; Mari JJ; Carroll KM
Drug Alcohol Depend; 2019 May; 198():126-132. PubMed ID: 30921648
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal association of preference-weighted health-related quality of life measures and substance use disorder outcomes.
Pyne JM; Tripathi S; French M; McCollister K; Rapp RC; Booth BM
Addiction; 2011 Mar; 106(3):507-15. PubMed ID: 21205046
[TBL] [Abstract][Full Text] [Related]
10. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.
Heinzerling KG; Briones M; Thames AD; Hinkin CH; Zhu T; Wu YN; Shoptaw SJ
J Neuroimmune Pharmacol; 2020 Jun; 15(2):238-248. PubMed ID: 31820289
[TBL] [Abstract][Full Text] [Related]
11. Course of Psychiatric Symptoms and Abstinence among Methamphetamine-Dependent Persons in Sober Living Recovery Homes.
Polcin DL; Witbrodt J; Korcha R; Gupta S; Mericle AA
J Psychoactive Drugs; 2016; 48(3):173-80. PubMed ID: 27184803
[TBL] [Abstract][Full Text] [Related]
12. Psychopathology in methamphetamine-dependent adults 3 years after treatment.
Glasner-Edwards S; Mooney LJ; Marinelli-Casey P; Hillhouse M; Ang A; Rawson RA;
Drug Alcohol Rev; 2010 Jan; 29(1):12-20. PubMed ID: 20078677
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for methamphetamine/amphetamine use disorder-a systematic review and meta-analysis.
Chan B; Freeman M; Kondo K; Ayers C; Montgomery J; Paynter R; Kansagara D
Addiction; 2019 Dec; 114(12):2122-2136. PubMed ID: 31328345
[TBL] [Abstract][Full Text] [Related]
14. Longer term improvement in neurocognitive functioning and affective distress among methamphetamine users who achieve stable abstinence.
Iudicello JE; Woods SP; Vigil O; Scott JC; Cherner M; Heaton RK; Atkinson JH; Grant I;
J Clin Exp Neuropsychol; 2010 Aug; 32(7):704-18. PubMed ID: 20198527
[TBL] [Abstract][Full Text] [Related]
15. Time to relapse following treatment for methamphetamine use: a long-term perspective on patterns and predictors.
Brecht ML; Herbeck D
Drug Alcohol Depend; 2014 Jun; 139():18-25. PubMed ID: 24685563
[TBL] [Abstract][Full Text] [Related]
16. Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinence.
Proebstl L; Krause D; Kamp F; Hager L; Manz K; Schacht-Jablonowsky M; Straif M; Riebschläger M; Neumann S; Schreiber A; Soyka M; Koller G
Psychiatry Res; 2019 Nov; 281():112599. PubMed ID: 31629302
[TBL] [Abstract][Full Text] [Related]
17. Changes in psychiatric symptoms among persons with methamphetamine dependence predicts changes in severity of drug problems but not frequency of use.
Polcin DL; Korcha R; Bond J; Galloway G; Nayak M
Subst Abus; 2016; 37(1):209-14. PubMed ID: 25775225
[TBL] [Abstract][Full Text] [Related]
18. Initial validation of a proxy indicator of functioning as a potential tool for establishing a clinically meaningful cocaine use outcome.
Kiluk BD; Babuscio TA; Nich C; Carroll KM
Drug Alcohol Depend; 2017 Oct; 179():400-407. PubMed ID: 28858744
[TBL] [Abstract][Full Text] [Related]
19. Withdrawal symptoms in abstinent methamphetamine-dependent subjects.
Zorick T; Nestor L; Miotto K; Sugar C; Hellemann G; Scanlon G; Rawson R; London ED
Addiction; 2010 Oct; 105(10):1809-18. PubMed ID: 20840201
[TBL] [Abstract][Full Text] [Related]
20. Frailty in Comorbid HIV and Lifetime Methamphetamine Use Disorder: Associations with Neurocognitive and Everyday Functioning.
Paolillo EW; Saloner R; Montoya JL; Campbell LM; Pasipanodya EC; Iudicello JE; Moore RC; Letendre SL; Jeste DV; Moore DJ
AIDS Res Hum Retroviruses; 2019; 35(11-12):1044-1053. PubMed ID: 31303012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
